Lasting Reduction in Toxicity Seen for MRI-Guided SBRT for Prostate Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 27, 2024 -- Magnetic resonance imaging (MRI) guidance for aggressive margin reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces two-year toxic effects, according to a study published online Nov. 13 in European Urology.
Amar U. Kishan, M.D., from the University of California, Los Angeles, and colleagues conducted a secondary analysis of a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer to compare the impact of AMR with MRI guidance versus computed tomography (CT) guidance.
The researchers found that the cumulative incidence of two-year physician-scored toxicity, defined as grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxic effects, were lower with MRI guidance. The cumulative incidence rates of late grade ≥2 toxicity at two years were 27 versus 51 percent for MRI- versus CT-guided SBRT for GU toxicity and 1.4 versus 9.5 percent for GI toxicity. The odds of a clinically relevant deterioration in bowel function according to the Expanded Prostate Cancer Index Composite-26 score and in the Sexual Health Inventory in Men score were significantly lower with MRI-guided SBRT (odds ratios, 0.444 and 0.366, respectively). The odds of a deterioration for other quality-of-life metrics did not differ significantly.
"This study adds strong evidence that the enhanced precision and accuracy afforded by MRI-guided SBRT leads to significantly fewer urinary, bowel, and sexual side effects for men receiving prostate SBRT," Kishan said in a statement.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Patients Mainly Prefer AI as Second Reader for Screening Mammogram
WEDNESDAY, April 23, 2025 -- Use of artificial intelligence (AI) as a second reader in screening mammography is accepted by patients, according to a study published online April...
Breast Cancer Outcomes Improved With History of Screening Mammography
MONDAY, April 21, 2025 -- Prior screening mammography is associated with earlier stage at breast cancer diagnosis and lower breast cancer mortality, according to a study published...
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.